Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
2(15%)
Results Posted
89%(8 trials)

Phase Distribution

Ph phase_3
6
46%
Ph phase_1
5
38%
Ph phase_2
1
8%

Phase Distribution

5

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
5(41.7%)
Phase 2Efficacy & side effects
1(8.3%)
Phase 3Large-scale testing
6(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(2)
Completed(9)
Terminated(1)
Other(1)

Detailed Status

Completed9
Active, not recruiting2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (41.7%)
Phase 21 (8.3%)
Phase 36 (50.0%)

Trials by Status

unknown18%
withdrawn18%
active_not_recruiting215%
completed969%

Recent Activity

2 active trials
Showing 5 of 13
active_not_recruiting

A Survey of Lanadelumab in Participants With Hereditary Angioedema

NCT05397431
completedphase_3

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

NCT05460325
completedphase_3

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

NCT04444895
active_not_recruitingphase_1

Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury

NCT04848272
unknownphase_2

Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)

NCT04278885
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT05397431

A Survey of Lanadelumab in Participants With Hereditary Angioedema

Active Not Recruiting
NCT05460325Phase 3

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Completed
NCT04444895Phase 3

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed
NCT04848272Phase 1

Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury

Active Not Recruiting
NCT04278885Phase 2

Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)

Unknown
NCT04206605Phase 3

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Completed
NCT04180163Phase 3

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

Completed
NCT04590586Phase 3

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

Completed
NCT04070326Phase 3

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children

Completed
NCT04503603Phase 1

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

Completed
NCT04422509Phase 1

Lanadelumab for Treatment of COVID-19 Disease

Completed
NCT03401671Phase 1

Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects

Completed
NCT04460105Phase 1

Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

Withdrawn

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13